NCT01571388View on ClinicalTrials.gov

A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
HealthyOtherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
Interventions
DRUG

dacomitinib

Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.

DRUG

dacomitinib

Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.

DRUG

dacomitinib

Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.

Trial Locations (2)

33143

Pfizer Investigational Site, South Miami

92801

Pfizer Investigational Site, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01571388 - A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment | Biotech Hunter | Biotech Hunter